Q&A: Dexcom CEO talks rapid pace of CGM innovation, what's coming in 2020 and beyond
Summary
One of the biggest digital health success stories of the two decades is in the diabetes space, especially the continuous glucose monitor (or CGM). Dexcom has been one of the undisputed leaders in this trend — it was the first company to get a CGM through the FDA that did not require fingerstick calibration and the first to connect directly to a phone. The company has seen impressive financial returns, but in some ways has struggled with its own success, running up against manufacturing capacity issues. On the sidelines of the JP Morgan Healthcare conference last week, MobiHealthNews sat down with Dexcom CEO Kevin Sayer to talk about his companys latest news, future plans, hot-button issues like noninvasive monitoring and CGMs for Type 2 diabetes, and the myth of "good problems" in healthcare. They have pens that are going to have Bluetooth connection capability and they’re working on an insulin delivery system as well for themselves, and our CGM will be integrated into the software platforms that they built.
Classifications
AskAI Classifications
LabelsLinked Companies
